Skip to main content
. 2022 Nov 24;12:1019911. doi: 10.3389/fonc.2022.1019911

Figure 2.

Figure 2

(A) Event-free survival of localized ASPS; (B) Progression-free survival for the observation group; (C) Progression-free survival for the PD-1 monotherapy group.